Blood-cytokine levels as adverse outcome predictors following biomaterial implant surgery


Reference #: 01566

The University of South Carolina is offering licensing opportunities for Blood-cytokine levels as adverse outcome predictors following biomaterial implant surgery


Despite the high number of patients undergoing reconstruction surgery with surgical mesh and the relatively high number of adverse outcomes, there are currently no published methods to predict undesired outcomes of this surgery.  In addition, adverse outcomes remain a possibility for other reconstruction surgeries with surgical mesh or other implant materials.

Invention Description:

This invention is a method that utilizes a patient’s blood sample to predict undesired surgical outcomes, which can then help surgeons and patients to make a better-informed decision on whether to proceed with surgery.

Potential Applications:

This innovative blood test can be performed using a patient’s blood sample to provide information about whether the patient might have an adverse surgical event.

Advantages and Benefits:

This innovation provides a not yet available means by which to minimize risk of adverse outcomes following biomaterial implant surgery, including but not limited to surgery to correct pelvic organ prolapse (POP).

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Levels of Immune Response Markers as Adverse Outcome Predictors Following Biomaterial Implant Surgery Utility United States 17/960,462   10/5/2022   10/5/2023 Published
Health Sciences
For Information, Contact:
Technology Commercialization
University of South Carolina
Melissa Moss
Mihyun Waugh
Nicholas Boltin
Lauren Wolf
Ronnie Horner
Matthew Hermes
Thomas Wheeler
Richard Goodwin
anti-inflammatory biotech
anti-inflammatory pharma
biomaterial implant
Blood samples
implant rejection
pelvic organ prolapse
predictive outcome
principal component analysis
surgical mesh
© 2024. All Rights Reserved. Powered by Inteum